Grufity logo
Grufity logo
BCTX

BCTX - BriaCell Therapeutics Corp. Stock Price, Fair Value and News

$2.87+0.13 (+4.74%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

BCTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCTX Price Action

Last 7 days

-9.7%

Last 30 days

-7.6%

Last 90 days

-38.7%

Trailing 12 Months

-91.1%

BCTX RSI Chart

BCTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCTX Valuation

Market Cap

20.8M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

6.8K

EV/EBITDA

0.55

Price/Free Cashflow

-0.73

BCTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

BCTX Fundamentals

BCTX Revenue

Revenue (TTM)

3.1K

BCTX Earnings

Earnings (TTM)

-29.6M

Earnings Growth (Yr)

-16.94%

Earnings Growth (Qtr)

12.6%

BCTX Profitability

EBT Margin

843319.78%

Return on Equity

-126.36%

Return on Assets

-109.27%

Free Cashflow Yield

-136.42%

BCTX Investor Care

Shares Dilution (1Y)

1005.58%

Diluted EPS (TTM)

-14.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2022----
2021--3.1K-
2020----
2019--12.0K-
2018--16.0K-
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About BriaCell Therapeutics Corp.

BCTX
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
0
 CEO
 WEBSITEbriacell.com
 SECTORHealthcare
 INDUSTRYBiotechnology

BriaCell Therapeutics Corp. Frequently Asked Questions

BCTX is the stock ticker symbol of BriaCell Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of BriaCell Therapeutics Corp. is 19.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, BCTX's PE ratio (Price to Earnings) is -0.67 and Price to Sales (PS) ratio is 6.84 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, BriaCell Therapeutics Corp. has provided -0.398 (multiply by 100 for percentage) rate of return.